Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma

被引:38
作者
Capriotti, Elisabetta [1 ]
Vonderheid, Eric C. [2 ]
Thoburn, Christopher J. [3 ]
Wasik, Mariusz A. [4 ,5 ]
Bahler, David W. [6 ]
Hess, Allan D. [3 ]
机构
[1] Univ Roma Tor Vergata, Dept Dermatol, Rome, Italy
[2] Johns Hopkins Med Inst, Dept Dermatol, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA
[5] Univ Penn, Lab Med, Philadelphia, PA 19104 USA
[6] Univ Utah, Dept Pathol, Salt Lake City, UT USA
关键词
lymphoma; Sezary syndrome; T-plastin; FoxP3; Mic-B; CD28; regulatory T-cell;
D O I
10.1080/10428190802064917
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Peripheral blood cells from 28 patients with leukemic cutaneous T-cell lymphoma including 25 patients with Sezary syndrome were evaluated for expression of regulatory T-cell-associated markers (FoxP3, CD25, CTLA-4, neurophilin-1), T-cell activation markers (CD28 and its ligands B7.1 and B7.2) and NK cell-associated markers (NKG2D and its ligands Mic-A and Mic-B) using real-time quantitative polymerase chain reaction. T-plastin served as a positive genetic marker, and its expression correlated to blood tumor burden. More than 90% of samples had transcripts for CD28 and Mic-B, but less than 30% of samples expressed FoxP3, CTLA-4 and CD25. Expression of Mic-B by neoplastic cells could provide another mechanism to inhibit anti-tumor immune responses. FoxP3 expression correlated with a poor prognosis. Although the underlying mechanisms accounting for this correlation remain unclear, the expression of the Foxp3 and CTLA-4 regulatory elements indicates that a subset of leukemic cases displays a regulatory T-cell phenotype.
引用
收藏
页码:1190 / 1201
页数:12
相关论文
共 96 条
[1]   Is FOXP3 expressed in cutaneous T-cell lymphomas? [J].
Banham, Alison H. ;
Brown, Philip J. ;
Lyne, Linden ;
Schulze, Hans-Joachim ;
Hallermann, Christian .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 80 (01) :90-91
[2]   Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer [J].
Bass, KK ;
Mastrangelo, MJ .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 47 (01) :1-12
[3]   Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells [J].
Berger, CL ;
Tigelaar, R ;
Cohen, J ;
Mariwalla, K ;
Trinh, J ;
Wang, NC ;
Edelson, RL .
BLOOD, 2005, 105 (04) :1640-1647
[4]   Prognostic factors in Sezary syndrome: A multivariate analysis of clinical, haematological and immunological features [J].
Bernengo, MG ;
Quaglino, P ;
Novelli, M ;
Cappello, N ;
Doveil, GC ;
Lisa, E ;
De Matteis, A ;
Fierro, MT ;
Appino, A .
ANNALS OF ONCOLOGY, 1998, 9 (08) :857-863
[5]   The relevance of the CD4+CD26-subset in the identification of circulating Sezary cells [J].
Bernengo, MG ;
Novelli, M ;
Quaglino, P ;
Lisa, F ;
De Matteis, A ;
Savoia, P ;
Cappello, N ;
Fierro, MT .
BRITISH JOURNAL OF DERMATOLOGY, 2001, 144 (01) :125-135
[6]   Regulatory T cells in cancer [J].
Beyer, Marc ;
Schultze, Joachim L. .
BLOOD, 2006, 108 (03) :804-811
[7]   Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+functional regulatory T-cells in patients with graft-versus-host disease [J].
Biagi, Ettore ;
Di Biaso, Iolanda ;
Leoni, Veronica ;
Gaipa, Giuseppe ;
Rossi, Vincenzo ;
Bugarin, Cristina ;
Renoldi, Giuliano ;
Parma, Matteo ;
Balduzzi, Adriana ;
Perseghin, Paolo ;
Biondi, Andrea .
TRANSPLANTATION, 2007, 84 (01) :31-39
[8]   Sezary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3 [J].
Booken, N. ;
Gratchev, A. ;
Utikal, J. ;
Weiss, C. ;
Yu, X. ;
Qadoumi, M. ;
Schmuth, M. ;
Sepp, N. ;
Nashan, D. ;
Rass, K. ;
Tueting, T. ;
Assaf, C. ;
Dippel, E. ;
Stadler, R. ;
Klemke, C-D ;
Goerdt, S. .
LEUKEMIA, 2008, 22 (02) :393-399
[9]   Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in Sezary syndrome patients [J].
Bouaziz, JD ;
Ortonne, N ;
Giustiniani, J ;
Schiavon, V ;
Huet, D ;
Bagot, M ;
Bensussan, A .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (06) :1273-1278
[10]   CD28 function: A balance of costimulatory and regulatory signals [J].
Bour-Jordan, H ;
Bluestone, JA .
JOURNAL OF CLINICAL IMMUNOLOGY, 2002, 22 (01) :1-7